BioSpace News Archive

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by the Central Adelaide Local Health Network Human Research Ethics Committee to commence a clinical trial of Cynata’s Cymerus™ mesenchymal stem cell product in patients with diabetic foot ulcers.

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that EXSERVAN™ (riluzole), the first oral film formulation of riluzole, is now available in the U.S. for the treatment of amyotrophic lateral sclerosis (ALS).

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a study in Pain Medicine that compared adolescent response to migraine medications to their response to Remote Electrical Neuromodulation (REN) administered by Nerivio®

Susan G. Komen today announced the awarding of 30 new grants to researchers at 18 leading institutions in the U.S. and Canada.

Scopus BioPharma Inc. today announced the acquisition of Los Angeles-based Olimmune Inc.

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced initiation of KARDIA-1, a global Phase 2 study evaluating the efficacy and safety of zilebesiran, an investigational subcutaneous RNAi therapeutic targeting liver-expressed angiotensinogen in development for the treatment of hypertension.

Aurinia Pharmaceuticals Inc. announced the recipients of five $50,000 grant awards to support implementation patient navigation programs targeted toward disadvantaged populations at most risk of developing SLE and LN.

Immunome, Inc. today announced the appointment of Andrew D. Badley, M.D., to the company’s COVID-19 Advisory Board.

OpGen, Inc. today announced prospective clinical data on the Unyvero LRT BAL presented during a webinar held on June 29, 2021, and data presented at the virtual World Microbe Forum, June 20-24, 2021.

Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation